XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
XTL Biopharmaceuticals Ltd. has entered into a settlement agreement involving an adjustment of American Depositary Shares and warrants with its subsidiary, The Social Proxy Ltd. The resolution saw the return of over 372 million ordinary shares to XTL’s treasury. XTL continues to explore strategic collaborations in the Lupus treatment space while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.